GSA Capital Partners LLP Purchases Shares of 9,917 Pfizer Inc. (PFE)
GSA Capital Partners LLP purchased a new position in shares of Pfizer Inc. (NYSE:PFE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 9,917 shares of the biopharmaceutical company’s stock, valued at approximately $360,000.
Several other large investors also recently bought and sold shares of PFE. HC Financial Advisors Inc. acquired a new stake in Pfizer in the 4th quarter valued at about $2,685,000. Fiduciary Trust Co. grew its stake in Pfizer by 0.6% in the 1st quarter. Fiduciary Trust Co. now owns 555,624 shares of the biopharmaceutical company’s stock valued at $19,719,000 after acquiring an additional 3,316 shares during the last quarter. Bank of The West grew its stake in Pfizer by 0.7% in the 1st quarter. Bank of The West now owns 250,109 shares of the biopharmaceutical company’s stock valued at $8,876,000 after acquiring an additional 1,679 shares during the last quarter. Strategic Wealth Advisors Group LLC grew its stake in Pfizer by 134.7% in the 1st quarter. Strategic Wealth Advisors Group LLC now owns 216,803 shares of the biopharmaceutical company’s stock valued at $7,694,000 after acquiring an additional 124,420 shares during the last quarter. Finally, PM CAPITAL Ltd grew its stake in Pfizer by 5.1% in the 1st quarter. PM CAPITAL Ltd now owns 852,715 shares of the biopharmaceutical company’s stock valued at $30,263,000 after acquiring an additional 41,740 shares during the last quarter. 68.96% of the stock is currently owned by institutional investors and hedge funds.
PFE has been the topic of a number of research reports. Cantor Fitzgerald reissued a “buy” rating and issued a $53.00 price objective on shares of Pfizer in a research note on Wednesday, October 17th. Morgan Stanley set a $45.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Thursday, September 13th. Barclays reissued a “neutral” rating and issued a $40.00 price objective on shares of Pfizer in a research note on Wednesday, September 26th. BMO Capital Markets reissued a “buy” rating and issued a $44.00 price objective on shares of Pfizer in a research note on Monday, August 27th. Finally, Goldman Sachs Group reissued a “neutral” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Tuesday, August 28th. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $42.67.
Pfizer stock opened at $44.28 on Friday. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $45.81. The stock has a market cap of $256.03 billion, a price-to-earnings ratio of 16.71, a PEG ratio of 2.17 and a beta of 0.88. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.91 and a current ratio of 1.16.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion for the quarter, compared to analyst estimates of $13.53 billion. Pfizer had a net margin of 44.63% and a return on equity of 25.34%. The company’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 3 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Friday, November 9th will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, November 8th. This represents a $1.36 annualized dividend and a dividend yield of 3.07%. Pfizer’s payout ratio is currently 51.32%.
COPYRIGHT VIOLATION NOTICE: “GSA Capital Partners LLP Purchases Shares of 9,917 Pfizer Inc. (PFE)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/11/10/gsa-capital-partners-llp-purchases-shares-of-9917-pfizer-inc-pfe.html.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Featured Story: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.